Veracyte's Genomic Tests to Guide Cancer Treatment Decisions at ASCO 2026
Veracyte, Inc., a prominent cancer diagnostics company, is set to present data from two significant phase III clinical trials at the 2026 ASCO Annual Meeting in Chicago. The trials, OPTIMA and ENZAMET, utilize Veracyte's Prosigna Breast and Decipher Prostate tests to guide treatment decisions in early-stage breast cancer and metastatic prostate cancer. The OPTIMA trial, led by University College London, enrolled over 4,400 patients to determine which individuals could benefit from chemotherapy and who might safely avoid it. The results, presented by Dr. Rob Stein, aim to provide Level 1A evidence supporting Prosigna-guided treatment decisions. Meanwhile, the ENZAMET trial, conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, evaluates the Decipher Prostate test's ability to predict treatment benefits with chemotherapy in metastatic prostate cancer. Dr. Christopher Sweeney will present these findings, highlighting the potential to personalize treatment intensity based on ... 
